29 January 2018

EDCTP and GHIT Fund co-fund the development of a pediatric formulation for schistosomiasis

On 8 December, the European & Developing Countries Clinical Trials Partnership (EDCTP) and The Global Health Innovative Technology Fund (GHIT) announced that they will be co-funding the Phase III clinical study conducted by the Pediatric Praziquantel Consortium. This study aims to provide clinical data and support for registration of a new praziquantel (PZQ) tablet formulation to treat schistosomiasis in preschool-aged children in sub-Saharan Africa.

The joint investment is the first action of a new partnership between EDCTP and GHIT, initiated to support product development research. EDCTP will be contributing €1,99M and GHIT €3,22M to the study consortium for a total project value of €12,10M including in-kind and cash contributions by all related parties.

Click here for the press release by EDCTP.
Click here for the press release by GHIT.